First a shout out to the physicians that helped make sense as to why this company was a buy! Thank you! To Adam F, you should stop....really you should. There are two things that helped me see the value and still help me believe this will go higher. 1) There is only one other drug on the market that can treat Platinum Resistant Ovarian Cancer. Now there are two :) 2) Time and time again in the conference calls, it was brought up on how they had designed the trial for NSCLC for a specific end state. I think a lot of analysts misunderstood this and got the data wrong. Endocyte's press release today said they have seen progress in another area where there are few drugs to treat. Personally, I think with the other drugs in the pipeline and once they start making money off of Europe that this company can continue to grow and do well. I do believe they are a buy out candidate. Remember how Merk's proprietary drug pool is shrinking and Endocyte just hired that one fellow to it's board who has been in 3 other take overs. I'm hoping for a share price of $130 at some point. I think this is likely if we can get FDA approval. 3k shares long!